SynderBio's system rapidly eliminates dead, dying cells, and/or non-malignant cells, and dissociates cell aggregates, to deliver a suspension of single, viable cells for analysis or diagnosis. Often there is a mixture of cancer and non-cancerous cells, which is routinely done during cancer diagnosis and is especially vital for Next-Generation Sequencing. Through faster, less labor intensive processing of tumor biopsies and other specimens, SynderBio’s technology benefits researchers, clinicians, pathologists, and patients.

Venture Information
Stage: 
Product Development
Industry: 
Medical Devices
Technology or Science Area: 
Instrument to isolate and evaluate cancer cells.
Market: 
Single cell analysis instrumentation and cancer diagnostic technologies market
Funding Round: 
Angel
Company Information
Founders: 
Michael Henry
Sarah Vigmostad
Mike Cable